Vaccines are the biological products that stimulate the immune system to protect the body against any foreign substance. The stimulated immune system destroys foreign particles and generates antibodies against it. Vaccine memorizes foreign substance and prevents immunity from invading the body in future. Cancer vaccines are drug categorized as biological modifiers to response; they stimulate the immune system that can fight against the disorder.
Peptide cancer vaccine creates a T-cell immune response, against tumor present in the body or it enhances pre-existing immune response against the tumor. There are different types of immunotherapy for cancer treatment which include antibody-drug conjugates, dendritic cell-based vaccines, monoclonal-based immunotherapy and peptide-based cancer vaccines. Cancer vaccines are the most commonly used vaccines due to user-friendly nature of product, easy manufacturing process, and effective mechanism. Peptide cancer vaccines are used under various clinical research protocols for treatment of solid tumours.
The occurrence of chronic diseases such as cancer of various types such as breast cancer, prostate cancer, gastric cancer, pancreatic cancer, lung cancer, and colorectal cancer has increased the demand for vaccines which drives the peptide cancer vaccine market. Also, failure of methods to treat the disorder effectively has led the demand for new immunotherapy treatment. The major factors restraining the peptide cancer vaccine market include the need for the special storage facility, transportation of vaccines, and lack of cancer vaccines in the remote areas.
Based on the regional analysis, the global peptide cancer market is segmented into North America, Europe, Asia-Pacific, and LAMEA. As per the estimation of National Cancer Institute, there were around 16.8 million new cases of cancer that were diagnosed in the U.S. in 2016, with approximately 6 lakhs deaths from the disorder. The number is expected to grow to 19 million by 2024. Several biotechnological and pharmaceutical companies are focusing on expanding into the Asia Pacific region to maximize the value of their research and development that will provide improved access to patients and provides low-cost operational efficiency to the manufacturers.
Merck & Co. in May 2018 invested US$ 125 million in the Moderna Therapeutics. The expansion includes partnering of mRNA-5671. The vaccine includes mRNA for the four common KRAS mutation that will cover most of the mutation treatment which occur in pancreatic cancer, colorectal cancer and non-small cell lung cancer (NSCLC). Moderna launched Phase I KEYNOTE-603 study in November 2017 of mRNA-4157. Korean government in March 2011 participated in Korean National Enterprise for the Clinical Trials, advancement in the country’s infrastructure and conducting the clinical trials that are expected to launch peptide cancer vaccine in the market.
This report provides analysis of the peptide cancer vaccine market that contains current industry trends, market size, market growth and demands, major players with their key strategies. It covers growth opportunities and market canvas in the coming years. The report has been made with an in-depth analysis along with inputs from the various industry experts. The research has been carried out with primary and secondary data sources and either supporting bottom-up or top-down approach.
Key players in the market are Immatics Biotechnologies, Galena Biopharma, Generex Biotechnology Corporation, BrightPath Biotherapeutics, BioLife Science, Lytix Biopharma, Antigen Express, Immune Design, Boston Biomedical and Enzo Life Science among others.
Global Composite Testing Market Segmentation:
• Preclinical Research
• Phase I
• Phase II
• Phase III
• Breast Cancer
• Prostate cancer
• Gastric cancer
• Pancreatic cancer
• Lung cancer
• Colorectal Cancer
• North America (U.S and Canada and rest of North America)
• Europe (Germany, France, Italy and Rest of Europe)
• Asia-Pacific (China, Japan, India, South Korea and Rest of Asia-Pacific)
• LAMEA (Brazil, Turkey, Saudi Arabia, South Africa and Rest of LAMEA)